| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.62 | 5e-41 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.47 | 2e-40 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.32 | 7e-21 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.28 | 2e-20 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.3 | 3e-18 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.3 | 2e-17 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.27 | 9e-14 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-13 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-13 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.26 | 9e-13 |